AlloVir Inc

NASDAQ:ALVR   3:59:41 PM EDT
34.31
+0.38 (+1.12%)
Earnings Announcements

Allovir Reports Third Quarter 2020 Financial Results

Published: 11/10/2020 12:51 GMT
(ALVR) - Allovir Reports Third Quarter 2020 Financial Results.
Q3 Loss per Share $0.58.
Q3 Earnings per Share Estimate $-0.30 -- Refinitiv Ibes Data (analyst estimates).
Phase 1/2 Clinical Trial With Alvr109, Our Virus-specific T Cell Therapy Designed to Combat Sars-cov-2 - Has Been Initiated.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.40

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.